Transforming Diabetic Foot Ulcer Care & Amputation Prevention with D’OXYVA
Circularity Healthcare and the Professional Educational Research Institute have partnered to address the alarming health issues highlighted by the recent global pandemic lockdowns, specifically focusing on the epidemic of diabetic foot ulcers (DFU) and associated amputations. Circularity’s primary focus is their unique use of D’OXYVA®, which has shown significant success in important pivotal human clinical trials. Circularity’s novel approach promises to transform diabetic foot ulcer care and amputation prevention with D’OXYVA by providing quick, cost-efficient, and noninvasive home treatment options even for the most severe DFUs.
That said, in this article we will review the press release with Circularity Healthcare and PERI, focusing on the promising effects of D’OXYVA on managing diabetic wounds. We will also explore the scientific basis of the therapy and how it compares to competitors on the market. Let’s get right into it…
What is DFU?
Before diving into the specifics of this press release, let’s first review the fundamentals of this medical condition based on the American Diabetes Association.
Diabetic foot ulcers, also known as DFUs, are a prevalent and serious consequence of diabetes mellitus. Diabetic individuals often develop chronic sores on their feet due to poor glycemic control, peripheral vascular disease, poor foot care, poor circulation, and immune system malfunction.(1)
DFUs are defined by the presence of open sores or wounds that can range from shallow to severe and vary in size. That said, diabetic foot ulcers present a substantial risk of preventable complications in diabetic people. They can result in a decrease in functional ability, infections, hospitalizations, lower-extremity amputations, and even death. The increasing lifespan and medical challenges faced by people with diabetes have led to a rising lifetime risk of having a foot ulcer, ranging from 19% to 34%.(2)
Extensive clinical trials have been conducted to find the best options for successful wound care due to the urgent demand. That said, let’s now look at the press release from Circularity Healthcare and PERI, representing a significant advancement in the search for innovative therapeutic solutions.
An Overview of Circularity Healthcare and PERI’s Press Release
Circularity Healthcare has initiated a groundbreaking effort to tackle the diabetic foot ulcers epidemic worsened by the COVID-19 pandemic. The partnership between Circularity Healthcare and the Professional Educational Research Institute (PERI) represents a significant change in diabetic wound care, seeking to transform treatment approaches by utilizing D’OXYVA in an innovative way.
To simply summarize the press release, this vastly expanded human pivotal clinical trial is centered on investigating the effectiveness of D’OXYVA in preventing amputations and treating DFUs, providing a hopeful alternative to traditional methods. A main benefit of D’OXYVA’s non-invasive transdermal administration technology is significantly improved blood flow in the microvascular system and cellular oxygen levels in tissues, that together accelerate so-called non-healing wound closure effectively to just a few weeks.
The trial, carried out in several top-ranked U.S. colleges, has the potential to provide revolutionary insights into DFU management, leading to significant breakthroughs in diabetic wound care. The press release ultimately highlights the need to tackle the increasing burden of DFUs and emphasizes the crucial role of D’OXYVA in transforming diabetic foot ulcer treatment.
How Has D’OXYVA Played a Role in This Clinical Trial?
Given the increase in diabetic foot ulcers during the pandemic, it has become a priority within certain medical communities, for example the NCBI, to learn about the condition and to develop innovative strategies to prevent amputations and accelerate wound healing within these patients. This specific clinical testing revealed several beneficial treatments, including non-surgical debridement agents, dressings, topical agents, oxygen therapies, negative pressure wound therapy, human growth factors, energy-based therapies, and systemic treatments.(3)
That said, the clinical trial that we are highlighting in this article with Circularity Healthcare utilizes D’OXYVA’s innovative transdermal delivery technology to harness its transformational potential. D’OXYVA’s noninvasive and cost-effective approach has the potential to revolutionize diabetic wound care by offering fast and readily accessible solutions to patients. Overall, Circularity Healthcare and PERI are working together to reduce the DFU epidemic using D’OXYVA to improve outcomes and quality of life for individuals with diabetic foot ulcers.
The Science Behind D’OXYVA
D’OXYVA functions through painless and noninvasive treatment to improve blood perfusion, tissue oxygenation, and wound healing. D’OXYVA also speeds the healing process by stimulating angiogenesis and boosting oxygen supply to damaged tissues through its transdermal delivery technique.
This novel method shows potential for individuals dealing with non-healing diabetic foot ulcers, providing a ray of hope amid the difficulties linked to traditional therapies. D’OXYVA has the potential to significantly improve diabetic wound care by addressing the underlying issue of reduced wound healing through enhancing oxygen delivery to the afflicted area.
D’OXYVA is a groundbreaking option for individuals dealing with the severe effects of DFUs due to its innovative method of action and positive clinical trial results. D’OXYVA is positioned to transform the standard of care for the treatment of diabetic wounds, providing renewed hope and enhanced quality of life for patients globally.
Market Analysis
The widespread occurrence of diabetic foot ulcers worldwide highlights the urgent requirement for treatment methods that are both effective and efficient. The economic and healthcare impact is substantial due to the millions of individuals globally impacted by DFUs. Conventional treatments frequently do not fully address the intricate pathophysiology of DFUs, emphasizing the crucial requirement for novel therapeutic strategies that can provide superior results.
That being said, D’OXYVA is a prominent option in the diabetic wound care sector. Its outstanding efficacy and cost-effectiveness distinguish it from existing approaches on the market. D’OXYVA provides a comprehensive therapy that targets the underlying cause of impede wound healing, unlike conventional treatments that may only provide partial relief or necessitate lengthy treatments. D’OXYVA also speeds up the healing process and lowers the chances of complications related to DFUs by improving blood flow, tissue oxygen levels, and the formation of new blood vessels.
D’OXYVA provides an effective solution for enhancing patient outcomes and reducing healthcare expenses as healthcare professionals and governments tackle the challenges of DFUs. Its demonstrated medical-effectiveness and cost-effectiveness position it as a leading treatment in the diabetic wound care industry, providing optimism for those impacted by this severe condition.
How Does D’OXYVA Compare to Other Competitors?
Multiple products in the diabetic wound care market compete for dominance, each presenting distinct approaches and advantages. That said, D’OXYVA stands out as a top competitor due to its exceptional clinical trial effectiveness and successful safety record demonstrated over a decade.(4)
D’OXYVA established itself as a trustworthy and validated solution in the field due to its regulatory approvals and clinical endorsements, distinguishing it from numerous competitors. D’OXYVA has consistently produced significant results, gaining the trust of both healthcare professionals and patients, unlike other approaches that have faced obstacles in producing substantial effects.
The achievement of D’OXYVA is also highly significant compared to other competitors in the industry. By setting a new standard for effectiveness and cost-efficiency in treating diabetic foot ulcers, it has changed the treatment options for people with this condition. Its capacity to accelerate wound healing, reduce amputations, and improve patient results establishes it as a leader in the diabetic wound care market.
In the future, as the need for efficient DFU treatments continues, D’OXYVA is positioned as a highly sought after diabetic wound care option. The proven effectiveness, safety, and cost-efficiency make it an attractive option for healthcare providers aiming to provide the best care to their patients. D’OXYVA serves as both a therapy method and a source of optimism for people with diabetes dealing with the difficulties of long-term wound healing.
Navigating Treatment Modalities and Costs in Diabetic Wound Care
Most healthcare providers offer multiple treatment choices for non-healing diabetic wounds, amputation prevention, and severe diabetes complication management. That said, each option has its own costs and effectiveness.
To start, conventional wound care methods like debridement and dressings necessitate regular trips to healthcare facilities, resulting in significant healthcare expenses in the long run. Advanced treatments such as Negative Pressure Wound Therapy or NPWT and Hyperbaric Oxygen Therapy or known as HBOT show potential benefits but can be costly and not widely available to patients.
However, D’OXYVA offers a distinctive alternative. D’OXYVA’s non-invasive transdermal administration technology lowers the necessity for frequent clinic visits, potentially decreasing overall treatment expenses. Furthermore, its ability to improve blood flow and oxygen levels in tissues leads to quick wound healing and reduces the risk of amputation without requiring intrusive techniques or costly equipment.
The usual cost of treatments such as NPWT and HBOT can vary from $250 to $600 per session, making them unaffordable for many patients due to the high cumulative expenses. On the other hand, D’OXYVA offers a cost-effective and simple option that surpasses traditional methods in terms of effectiveness, accessibility, and price for managing diabetic wounds and complications.(5)
How Has D’OXYVA Played a Role in Other Medical Fields?
D’OXYVA has expanded its impact beyond diabetic wound care to provide valuable contributions in other medical fields and industries. The unique transdermal delivery technology and its capacity to improve blood perfusion and tissue oxygenation have been utilized in areas beyond the management of DFU.
D’OXYVA has shown effectiveness in enhancing microcirculation and oxygen levels in cardiovascular health, providing possible advantages for those with cardiovascular conditions, hypertension, and peripheral artery disease. Furthermore, its noninvasive characteristics and user-friendly design make it an appealing choice for people looking for alternative treatments for circulatory problems.
D’OXYVA has also demonstrated potential in sports medicine and improving athletic performance by aiding in quicker recovery from physical effort and injuries. Athletes and fitness enthusiasts have widely adopted D’OXYVA to enhance their physical performance and reduce recovery times.
In addition, D’OXYVA is used in cosmetic and wellness industries to enhance blood flow, sleep, stamina, skin health and oxygen levels, making it popular for skin renewal and wound healing. Its noninvasive characteristics and positive safety record make it a popular choice for those seeking to improve their general health for people of all ages.(6)
D’OXYVA’s many benefits highlight its adaptability and effectiveness in meeting different medical requirements and sectors, providing promise for better health results and increased quality of life globally.
An Overview: Dealing with the Epidemic of Diabetic Foot Ulcers
As we know from the American Diabetes Association, DFUs are a major health issue, especially during the COVID-19 pandemic. Extended lockdowns and limited mobility have worsened the risk factors for DFUs, making diabetes patients more vulnerable. The partnership between Circularity Healthcare and PERI has been crucial, providing hope for people dealing with DFUs. As shown in the press release, D’OXYVA has the potential to reduce the negative effects of DFUs on patients and healthcare systems globally by accelerating wound healing and reducing amputations.
In the ever-changing field of diabetic wound care, advancements such as D’OXYVA provide hope for both patients and healthcare providers. D’OXYVA has the potential to alter the standard of care for DFUs, offering help for those suffering from this serious and difficult ailment.
Learn More About the Benefits of D’OXYVA for DFU’s
D’OXYVA has been shown to be a notable and effective treatment for DFUs on a global scale. This treatment approach is not only cost-effective but also offers transformative options for diabetic wound care. Reach out to us or visit our website to discover how D’OXYVA is revolutionizing diabetic wound care and how it may benefit you or a loved one.
References
1. MicroGenDX, Diabetic Foot Ulcer (DFU). Reference
2. Diabetes Care 2023. Caitlin W. Hicks. Reference
3. NCBI- Update on management of diabetic foot ulcers. Published in final edited form as Ann N Y Acad Sci. 2018. Reference from: PMC5793889
4. Bio Space- Published, Feb 01, 2021. Reference
5. Dr. Alan Katz, National Medical Director of Hyperbaric Medical Solutions (HMS). Reference
6. Edi Medical Products. Reference
